非小细胞肺癌中CD73的调控机制
该研究利用TCGA数据分析CD73在癌症中的表达,并在多种非小细胞肺癌(NSCLC)细胞系及患者来源类器官中,通过药物或遗传抑制EGFR、MEK、KRAS或ALK,发现可显著降低CD73 mRNA和蛋白表达;c-Jun过表达诱导CD73表达,ChIP证实c-Jun结合CD73基因组区域,提示CD73受ERK-Jun通路调控。
要点
- CD73在多种癌症类型中高表达。
- 抑制EGFR、MEK、KRAS或ALK可降低NSCLC细胞及类器官中CD73 mRNA和蛋白表达。
- c-Jun过表达诱导CD73表达,且c-Jun结合CD73基因组区域,提示ERK-Jun通路调控CD73。
核心结论
- 在EGFR突变、KRAS突变或ALK重排的NSCLC癌细胞和患者来源类器官中CD73表达较高。
- 机制上,CD73受ERK-Jun通路调控,其中c-Jun通过结合CD73基因组区域调控CD73表达。
研究设计与样本
- 研究利用TCGA数据分析癌症患者中CD73表达。
- 在多种NSCLC癌细胞系和患者来源类器官中,采用蛋白质印迹、qPCR和ChIP-PCR探索CD73表达的调控。
主要发现
- CD73在多种癌症类型中高表达。
- 药物或遗传抑制EGFR、MEK、KRAS或ALK可显著降低EGFR突变、KRAS突变或ALK重排的NSCLC癌细胞和患者来源类器官中CD73 mRNA和蛋白表达。
- c-Jun过表达诱导CD73 mRNA和蛋白表达。
- ChIP实验显示c-Jun结合CD73基因组区域。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung cancer is the leading cause of global cancer-related mortality. Although immune checkpoint therapy has achieved remarkable results in lung cancer, EGFR-mutant or ALK-positive non-smallcell lung cancer patients show limited benefit. Besides the low tumor mutational burden, PD-L1 expression and CD8+ tumor-infiltrating T cells, upregulation of CD73/adenosine pathway also contributes to the immune-inert microenvironment of EGFR-mutant NSCLC. However, the detailed mechanism underlying the regulation of CD73 is unclear. METHODS: TCGA data was used to analyze the CD73 expression in cancer patients. Western blotting, qPCR, and ChIP-PCR were performed in multiple NSCLC cancer cell lines and patient derived organoids were used to explore the regulation of CD73 expression using western blotting. RESULTS: CD73 expression was highly expressed in multiple cancer types. Pharmacological or genetic inhibition of EGFR, MEK, KRAS, or ALK dramatically reduced the CD73 mRNA and protein expression in NSCLC cancer cells and patient-derived organoids with EGFR mutation, KRAS mutation or ALK-rearrangement. C-Jun overexpression-induced CD73 mRNA and protein expression. ChIP assay showed that c-Jun bind to CD73 genomic regions. CONCLUSIONS: Higher CD73 expression in NSCLC cancer cells and patient-derived organoids with EGFR mutation, KRAS mutation or ALK-rearrangement. Mechanistically, CD73 is regulated by ERK-Jun pathway, wherein c-Jun regulates CD73 expression via binding to CD73 genomic regions.
引用
- Han Y, Lee T, He Y, et al. The regulation of CD73 in non-small cell lung cancer. Eur J Cancer. 2022. PMID: 35598361. doi:10.1016/j.ejca.2022.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。